Gabrielle Jongeneel

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 6

Top Topics

Ejection Fraction

Metastatic Colorectal Cancer

Top Venues

Therapeutic advances in gastroenterology

International journal of cancer

The European journal of health economics : HEPAC : health economics in prevention and care

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, Miriam Koopman, Geraldine R Vink, Cornelis J A Punt, Veerle M H Coupé
Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Therapeutic advances in gastroenterology 14 (2021)
Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, Jos W R Twisk, Miriam Koopman, Cornelis J A Punt, Geraldine R Vink, Veerle M H Coupé
Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study. International journal of cancer 148 (11) (2021)
Gabrielle Jongeneel, Marjolein J E Greuter, Natalia Kunst, Felice N van Erning, Miriam Koopman, Jan P Medema, Louis Vermeulen, Jan Nicolaas Maria IJzermans, Geraldine R Vink, Cornelis J A Punt, Veerle M H Coupé
Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30 (9) (2021)
Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, Miriam Koopman, Geraldine R Vink, Cornelis J A Punt, Veerle M H Coupé
Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. Therapeutic advances in gastroenterology 13 (2020)
Gabrielle Jongeneel, Marjolein J E Greuter, Felice N van Erning, Miriam Koopman, Jan P Medema, Raju Kandimalla, Ajay Goel, Luis Bujanda, Gerrit A Meijer, Remond J A Fijneman, Martijn G H van Oijen, Jan Ijzermans, Cornelis J A Punt, Geraldine R Vink, Veerle M H Coupé
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN). The European journal of health economics : HEPAC : health economics in prevention and care 21 (7) (2020)
Gabrielle Jongeneel, Thomas Klausch, Felice N van Erning, Geraldine R Vink, Miriam Koopman, Cornelis J A Punt, Marjolein J E Greuter, Veerle M H Coupé
Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. International journal of cancer 146 (11) (2019)